← Back to Treatments
🏅 FDA Orphan Designation

Kygevvi

doxecitine and doxribtimine

Manufacturer: UCB, Inc.

Indicated for:
Mitochondrial DNA depletion syndromeOrphan

FDA-Approved Indications (1)

Treatment of patients 1 year of age and older with thymidine kinase 2 (TK2) deficiency (TK2-MDS, myopathic form). Doxecitine and doxribtimine are pyrimidine nucleoside analogs that restore mitochondri…

Indications & Usage

1 INDICATIONS AND USAGE KYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. ( 1 )

💙 Support Programs

View all →
Kygevvi
UCB, Inc.
Apply ↗
KYGEVVI
Adaptimmune
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.